Axon Enterprise (NASDAQ:AXON) Director Sells $295,403.56 in Stock

Axon Enterprise, Inc (NASDAQ:AXON) Director Jeri Williams sold 629 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $469.64, for a total value of $295,403.56. Following the completion of the sale, the director directly owned 1,141 shares of the company’s stock, valued at approximately $535,859.24. This trade represents a 35.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jeri Williams also recently made the following trade(s):

• On Tuesday, March 17th, Jeri Williams sold 157 shares of Axon Enterprise stock. The shares were sold at an average price of $490.00, for a total value of $76,930.00.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $513.20 on Friday. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $885.91. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. The business has a fifty day moving average of $407.52 and a two-hundred day moving average of $491.96. The company has a market cap of $41.36 billion, a P/E ratio of 206.10, a price-to-earnings-growth ratio of 8.75 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The company had revenue of $807.35 million during the quarter, compared to the consensus estimate of $778.91 million. During the same quarter last year, the company earned $1.47 earnings per share. Axon Enterprise’s quarterly revenue was up 33.7% compared to the same quarter last year. As a group, analysts predict that Axon Enterprise, Inc will post 1.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of recent analyst reports. Royal Bank Of Canada reduced their target price on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a report on Wednesday, February 25th. UBS Group decreased their price objective on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. Zacks Research raised shares of Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Finally, The Goldman Sachs Group set a $535.00 price objective on shares of Axon Enterprise in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $712.75.

Institutional Trading of Axon Enterprise

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC raised its position in shares of Axon Enterprise by 7.2% in the first quarter. Parallel Advisors LLC now owns 1,095 shares of the biotechnology company’s stock valued at $465,000 after buying an additional 74 shares during the last quarter. NewEdge Advisors LLC raised its position in shares of Axon Enterprise by 32.4% in the first quarter. NewEdge Advisors LLC now owns 5,315 shares of the biotechnology company’s stock valued at $2,257,000 after buying an additional 1,301 shares during the last quarter. Foguth Wealth Management LLC. acquired a new position in shares of Axon Enterprise in the first quarter valued at approximately $541,000. Dala Group LLC acquired a new position in shares of Axon Enterprise in the first quarter valued at approximately $1,313,000. Finally, Keel Point LLC raised its position in shares of Axon Enterprise by 4.4% in the first quarter. Keel Point LLC now owns 599 shares of the biotechnology company’s stock valued at $254,000 after buying an additional 25 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.